X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs PANACEA BIOTECH - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD PANACEA BIOTECH STRIDES SHASUN LTD/
PANACEA BIOTECH
 
P/E (TTM) x 13.2 171.2 7.7% View Chart
P/BV x 1.5 3.8 40.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES SHASUN LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
PANACEA BIOTECH
Mar-14
STRIDES SHASUN LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,275149 857.2%   
Low Rs91882 1,115.4%   
Sales per share (Unadj.) Rs389.684.1 463.0%  
Earnings per share (Unadj.) Rs28.0-18.3 -152.8%  
Cash flow per share (Unadj.) Rs48.9-6.7 -729.9%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs303.183.7 362.1%  
Shares outstanding (eoy) m89.4261.25 146.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.4 205.0%   
Avg P/E ratio x39.2-6.3 -621.3%  
P/CF ratio (eoy) x22.4-17.2 -130.0%  
Price / Book Value ratio x3.61.4 262.1%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m98,0367,074 1,385.8%   
No. of employees `0005.82.8 210.9%   
Total wages/salary Rs m5,8811,449 405.8%   
Avg. sales/employee Rs Th6,005.91,874.1 320.5%   
Avg. wages/employee Rs Th1,014.0527.0 192.4%   
Avg. net profit/employee Rs Th431.2-407.7 -105.7%   
INCOME DATA
Net Sales Rs m34,8345,154 675.9%  
Other income Rs m1,686100 1,689.2%   
Total revenues Rs m36,5205,254 695.2%   
Gross profit Rs m6,428-766 -838.8%  
Depreciation Rs m1,872711 263.2%   
Interest Rs m2,2691,503 151.0%   
Profit before tax Rs m3,973-2,881 -137.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m4-6 -63.2%   
Extraordinary Inc (Exp) Rs m-1,0061,771 -56.8%   
Tax Rs m47017 2,797.6%   
Profit after tax Rs m2,501-1,121 -223.0%  
Gross profit margin %18.5-14.9 -124.1%  
Effective tax rate %11.8-0.6 -2,028.3%   
Net profit margin %7.2-21.8 -33.0%  
BALANCE SHEET DATA
Current assets Rs m38,1653,810 1,001.7%   
Current liabilities Rs m30,4028,365 363.4%   
Net working cap to sales %22.3-88.4 -25.2%  
Current ratio x1.30.5 275.6%  
Inventory Days Days77156 49.7%  
Debtors Days Days10467 155.4%  
Net fixed assets Rs m37,63914,480 259.9%   
Share capital Rs m89461 1,458.7%   
"Free" reserves Rs m26,210903 2,902.3%   
Net worth Rs m27,1055,127 528.6%   
Long term debt Rs m16,3775,832 280.8%   
Total assets Rs m81,16819,433 417.7%  
Interest coverage x2.8-0.9 -300.1%   
Debt to equity ratio x0.61.1 53.1%  
Sales to assets ratio x0.40.3 161.8%   
Return on assets %5.92.0 299.2%  
Return on equity %9.2-21.9 -42.2%  
Return on capital %12.13.6 331.4%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m13,4651,539 874.8%   
Fx outflow Rs m4,076942 432.7%   
Net fx Rs m9,389597 1,572.2%   
CASH FLOW
From Operations Rs m2,881599 480.9%  
From Investments Rs m-7,051-438 1,610.2%  
From Financial Activity Rs m3,382-303 -1,117.7%  
Net Cashflow Rs m-788-141 557.4%  

Share Holding

Indian Promoters % 27.7 74.5 37.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.6 6,300.0%  
FIIs % 8.6 1.3 661.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 23.6 109.7%  
Shareholders   56,241 10,259 548.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS